Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03963518
NCT03963518CompletedNot Applicable

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials

Institut Bergonié1 site in 1 country631 target enrollmentStarted: January 1, 2017Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
631
Locations
1
Primary Endpoint
Correlation Between Time to Next Treatment or Death (TNT-D) and Overall Survival (OS)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigate

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Control

nivolumab monotherapy

Intervention: nivolumab monotherapy (Drug)

Experimental

nivolumab plus ipilimumab

Intervention: nivolumab plus ipilimumab (Drug)

Outcomes

Primary Outcomes

Correlation Between Time to Next Treatment or Death (TNT-D) and Overall Survival (OS)

Time Frame: 4 years after the start of treatment

Correlation between Time to next treatment or death (TNT-D) and overall survival (OS) in previously untreated advanced melanoma patients.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Phase 2
Immunotherapy Study for Patients With Stage IV MelanomaStage IV MelanomaMetastatic Melanoma
NCT02054520NewLink Genetics Corporation47
Terminated
Phase 2
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaUrothelial Carcinoma
NCT04322643Case Comprehensive Cancer Center4
Recruiting
Phase 2
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy StrategyRadiation TherapyImmunotherapyChemotherapyEsophageal Cancer
NCT05817201Taizhou Hospital60
Completed
Phase 1
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerNon-small Cell Lung Cancer
NCT01998126University of Utah14
Unknown
Phase 3
Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAAAcquired Aplastic Anemia.
NCT01844635Nagoya University320